{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(7)"],"submitter":["Turchin A"],"pubmed_abstract":["<h4>Importance</h4>Sulfonylureas are commonly used to treat type 2 diabetes (T2D). Research findings on cardiovascular risk associated with sulfonylureas have been inconsistent.<h4>Objective</h4>To emulate a target trial that compares the risk of cardiovascular events after initiation of treatment with individual sulfonylureas or dipeptidyl peptidase 4 inhibitors (DPP4is).<h4>Design, setting, and participants</h4>This comparative effectiveness research study included individuals with T2D and moderate cardiovascular risk treated with metformin monotherapy who received care at 1 of 10 US health systems or were insured by 1 of 2 large health insurance plans between January 1, 2014, and January 1, 2023. Data were analyzed from July 2024 to March 2025.<h4>Exposure</h4>Initiation of treatment wi"],"journal":["JAMA network open"],"pagination":["e2523067"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12290728"],"repository":["biostudies-literature"],"pubmed_title":["Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors."],"pmcid":["PMC12290728"],"pubmed_authors":["DeVries A","Turchin A","Kaul AF","Hegermiller E","Carnahan R","McDonnell ME","Nair V","Goel S","Priest E","Hernan MA","Lansang MC","Petito LC","Willey VJ"],"additional_accession":[]},"is_claimable":false,"name":"Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors.","description":"<h4>Importance</h4>Sulfonylureas are commonly used to treat type 2 diabetes (T2D). Research findings on cardiovascular risk associated with sulfonylureas have been inconsistent.<h4>Objective</h4>To emulate a target trial that compares the risk of cardiovascular events after initiation of treatment with individual sulfonylureas or dipeptidyl peptidase 4 inhibitors (DPP4is).<h4>Design, setting, and participants</h4>This comparative effectiveness research study included individuals with T2D and moderate cardiovascular risk treated with metformin monotherapy who received care at 1 of 10 US health systems or were insured by 1 of 2 large health insurance plans between January 1, 2014, and January 1, 2023. Data were analyzed from July 2024 to March 2025.<h4>Exposure</h4>Initiation of treatment wi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-27T17:03:31.422Z","creation":"2025-08-28T03:08:48.436Z"},"accession":"S-EPMC12290728","cross_references":{"pubmed":["40705329"],"doi":["10.1001/jamanetworkopen.2025.23067"]}}